Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,787 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of COVID-19 pandemic on emergency medical system and management strategies in patients with acute coronary syndrome.
Saiin K, Takenaka S, Nagai T, Takahashi A, Mizuguchi Y, Konishi T, Anzai T, Hotta D, Kamigaki M, Yamazaki S, Fujita T, Yamashita T, Kawahatsu K, Suzuki T, Nozaki Y, Sakurada T, Takenaka T, Igarashi Y, Makino T; Sapporo city Acute Coronary Syndrome Network. Saiin K, et al. Among authors: makino t. Sci Rep. 2023 Mar 29;13(1):5120. doi: 10.1038/s41598-023-32223-1. Sci Rep. 2023. PMID: 36991026 Free PMC article.
[Coronary ectasia].
Tateda K, Makino T, Hirasawa K. Tateda K, et al. Among authors: makino t. Ryoikibetsu Shokogun Shirizu. 1996;(12):589-92. Ryoikibetsu Shokogun Shirizu. 1996. PMID: 9047545 Review. Japanese. No abstract available.
Erfolgreiche Behandlung eines Anti‐P200‐Pemphigoids in Verbindung mit Plaque‐Psoriasis mit Guselkumab: Successful treatment with guselkumab of anti‐p200 pemphigoid associated with plaque psoriasis.
Kitayama S, Makino T, Kataoka K, Mori S, Takemoto K, Furukawa F, Torai R, Hayashi M, Mizawa M, Ishii N, Hashimoto T, Shimizu T. Kitayama S, et al. Among authors: makino t. J Dtsch Dermatol Ges. 2024 May;22(5):713-716. doi: 10.1111/ddg.15364_g. J Dtsch Dermatol Ges. 2024. PMID: 38730518 German. No abstract available.
Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort.
Makino T, Nakai S, Momose K, Yamashita K, Tanaka K, Miyata H, Yamamoto S, Motoori M, Kimura Y, Ushimaru Y, Hirao M, Matsuyama J, Akamaru Y, Kurokawa Y, Eguchi H, Doki Y. Makino T, et al. Esophagus. 2024 May 8. doi: 10.1007/s10388-024-01056-w. Online ahead of print. Esophagus. 2024. PMID: 38717686
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.
Kato K, Doki Y, Chau I, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Makino T, Blum Murphy M, Amaya-Chanaga C, Patel A, Hu N, Matsumura Y, Kitagawa Y, Ajani J. Kato K, et al. Among authors: makino t. Cancer Med. 2024 May;13(9):e7235. doi: 10.1002/cam4.7235. Cancer Med. 2024. PMID: 38716626 Free PMC article. Clinical Trial.
1,787 results